It appears there may be some confusion regarding the entities involved. Percheron Therapeutics Limited (formerly Antisense Therapeutics Limited) is an Australian biotechnology company listed on the ASX under the ticker PER. According to recent shareholder information, HSBC Custody Nominees (Australia) Limited holds approximately 11.21% of Percheron's shares, while Platinum Investment Management Limited holds about 10.70%.
If HSBC has increased its stake in Percheron, potentially surpassing Platinum's holdings, this could be interpreted as a positive development. Institutional investors like HSBC often conduct thorough due diligence before making significant investments, which may reflect confidence in Percheron's prospects. However, it's important to note that institutional investments are just one of many factors to consider when evaluating a company's potential.
from Chatgbt ☝️
PER Price at posting:
7.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)